Tom Claeys
Overview
Explore the profile of Tom Claeys including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
716
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jamaer C, Berquin C, Claeys T, De Bleser E, Hoebeke P, Van Laecke E, et al.
J Pediatr Urol
. 2023 Apr;
19(4):482-483.
PMID: 37055342
Introduction: Pyeloplasty (open or Robot-assisted) is the gold standard of a symptomatic UPJ stenosis. Sometimes anatomic variants make the procedure challenging. This video describes a step-by-step approach in three settings:...
2.
Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, et al.
BJU Int
. 2021 Jul;
129(6):699-707.
PMID: 34289231
Objectives: To investigate the role of cytoreductive radical prostatectomy in addition to standard of care for patients with newly diagnosed metastatic prostate cancer. Materials And Methods: This multicentre, prospective study...
3.
Grammens J, Schechter M, Desender L, Claeys T, Sinatti C, VandeWalle J, et al.
Front Surg
. 2021 Apr;
8:649418.
PMID: 33842532
Kidney transplantation is universally recognized as the gold standard treatment in patients with End-stage Kidney Disease (ESKD, or according to the latest nomenclature, CKD stage 5). Robot-assisted kidney transplantation (RAKT)...
4.
Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, et al.
World J Urol
. 2018 Dec;
37(12):2557-2564.
PMID: 30578441
Purpose: Patients with oligometastatic prostate cancer (PC) may benefit from metastasis-directed therapy (MDT), delaying disease progression and the start of palliative systemic treatment. However, a significant proportion of oligometastatic PC...
5.
De Visschere P, Pattyn E, Ost P, Claeys T, Lumen N, Villeirs G
J Belg Soc Radiol
. 2018 Jul;
100(1):108.
PMID: 30038991
Objective: To compare the performance of PI-RADSv2 with PI-RADSv1 in patients with elevated PSA before biopsy. Methods: 245 patients with elevated PSA underwent mpMRI before biopsy between May 2011 and...
6.
Waterloos M, Claeys T, Sempels M, Van Laecke E, Hoebeke P, Spinoit A
J Pediatr Urol
. 2018 Mar;
14(2):198-199.
PMID: 29551555
The adrenogenital syndrome is an autosomal recessive disorder in which an enzyme defect in the steroid pathway leads to excessive prenatal exposure of androgens. In the female fetus, masculinization of...
7.
Buelens S, Claeys T, Dhondt B, Poelaert F, Vynck M, Yigit N, et al.
Clin Genitourin Cancer
. 2018 Jan;
16(3):197-205.e5.
PMID: 29366632
Background: Resistance mechanisms in the androgen receptor (AR) signaling pathway remain key drivers in the progression to castration-resistant prostate cancer (CRPC) and relapse under antihormonal therapy. Materials And Methods: We...
8.
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al.
J Clin Oncol
. 2017 Dec;
36(5):446-453.
PMID: 29240541
Purpose Retrospective studies suggest that metastasis-directed therapy (MDT) for oligorecurrent prostate cancer (PCa) improves progression-free survival. We aimed to assess the benefit of MDT in a randomized phase II trial....
9.
De Bruycker A, Lambert B, Claeys T, Delrue L, Mbah C, De Meerleer G, et al.
BJU Int
. 2017 Jun;
120(6):815-821.
PMID: 28646594
Objectives: To describe the anatomical patterns of prostate cancer (PCa) recurrence after primary therapy and to investigate if patients with low-volume disease have a better prognosis as compared with their...
10.
Claeys T, Lumen N, Kumps C, Praet M, De Meerleer G, Rottey S, et al.
Urol Oncol
. 2017 Feb;
35(4):152.e13-152.e22.
PMID: 28153420
Objectives: To describe the effects of cytoreductive nephrectomy (CN) on the natural course of metastatic renal cell carcinoma (mRCC). CN appears to stabilize metastatic lesions in mRCC in a subgroup...